LinkedIn · May 2025
Company post highlighting its AI-powered programmable delivery system and the challenges of mRNA delivery.
Cell-specific genetic medicines
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Nuntius Therapeutics is a London-based biotechnology company founded in 2021 that develops cell-specific genetic medicines and mRNA therapies using proprietary dendrimer-lipid nanocarriers, machine learning, and nucleic-acid engineering; its disclosed pipeline targets cancer, lung disease, neurodegenerative disease, and immunotherapy.
Primary product
Proprietary cell-specific mRNA / genetic-medicine delivery platform (dendrimer-lipid nanocarriers)
Founded
2021
Headquarters
London, United Kingdom
Team size
1-10
Industry
Biotechnology Research
Sub-industry
mRNA therapeutics / genetic medicine delivery
Offices
Open Positions
0 jobs at Nuntius Therapeutics
No open positions
Check back later for new openings